title: Low-dose aspirin does not improve ovarian responsiveness or pregnancy rate in IVF and ICSI patients: a randomized, placebo-controlled double-blind study.
abstract: BACKGROUND
  Poor ovarian and endometrial responses to gonadotrophin stimulation in assisted reproduction techniques lead to decreased pregnancy rates. The aim of the present study was to test the hypothesis that low-dose aspirin started prior to controlled ovarian stimulation improves ovarian responsiveness, pregnancy rate (PR) and pregnancy outcome.
  
  
  METHODS
  A total of 374 women who were to undergo IVF/ICSI were randomized to receive 100 mg of aspirin (n=186) or placebo (n=188) daily. Treatment was started on the first day of controlled ovarian stimulation. It was continued until menstruation or a negative pregnancy test. Pregnant women continued the medication until delivery. The main outcome measures were the number of oocytes, number and quality of embryos, the clinical PR and pregnancy outcome.
  
  
  RESULTS
  The mean (+/-SD) number of oocytes (12.0+/-7.0 versus 12.7+/-7.2), the total mean number of embryos (5.82+/-4.35 versus 5.99+/-4.66), the mean number of top quality embryos (0.99+/-1.39 versus 1.18+/-1.51) and the number of embryos transferred (1.64+/-0.64 versus 1.63+/-0.71) did not differ in the aspirin and placebo groups. Between the aspirin and placebo group, there was no statistically significant difference in clinical PR per embryo transfer (25.3%, n=44 out of 174 versus 27.4%, n=48 out of 175) or clinical PR per cycle initiated (23.7% versus 25.5%). Birth rate per embryo transfer did not differ significantly between the aspirin (18.4%) and placebo (21.1%) groups. The incidence of poor responders [12 (6.5%) versus 13 (6.9%)] was similar in both groups.
  
  
  CONCLUSIONS
  The present results indicate that low-dose aspirin treatment does not have any beneficial effect on ovarian responsiveness, PR and pregnancy outcome in unselected women undergoing IVF/ICSI.
authors.affiliation: Department of Obstetrics and Gynecology, University of Oulu, Infertility Clinic, Family Federation of Finland, 90220 Oulu, Finland. mervi.pakkila@oulu.fi
authors.forename: M
authors.initials: M
authors.lastname: Päkkilä
authors.forename: J
authors.initials: J
authors.lastname: Räsänen
authors.forename: S
authors.initials: S
authors.lastname: Heinonen
authors.forename: H
authors.initials: H
authors.lastname: Tinkanen
authors.forename: L
authors.initials: L
authors.lastname: Tuomivaara
authors.forename: K
authors.initials: K
authors.lastname: Mäkikallio
authors.forename: M
authors.initials: M
authors.lastname: Hippeläinen
authors.forename: J S
authors.initials: JS
authors.lastname: Tapanainen
authors.forename: H
authors.initials: H
authors.lastname: Martikainen
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D010053:Ovary / Q000166:cytology* / Q000187:drug effects; D010062:Ovulation Induction; D010919:Placebos; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D020554:Sperm Injections, Intracytoplasmic; D017211:Treatment Failure
chemical_list: D016861:Cyclooxygenase Inhibitors; D010919:Placebos; D001241:Aspirin